A Prospective Observational Study on the Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.

Sun Yat-sen University1 site in 1 country500 target enrollmentJune 1, 2022

ConditionsLung Cancer Esophageal Cancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Lung Cancer
Sponsor: Sun Yat-sen University
Enrollment: 500
Locations: 1
Primary Endpoint: Incidence of >=Grade 3 toxicities
Status: Recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study aims to assess the level of participation of thoracic cancer patients undergoing definitive radiotherapy and chemotherapy ± immunotherapy in their medical processes and the association between the level of participation and patients' side effects, quality of life, and long-term survival. Additionally, this study will rate the level of participation from both the patients' and medical staff's perspectives and will compare the differences in ratings from these two viewpoints, as well as their impact on treatment outcomes.

Registry

clinicaltrials.gov

Start Date

June 1, 2022

End Date

May 30, 2027

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

Sun Yat-sen University

Responsible Party

Principal Investigator

Hui Liu

Professor

Sun Yat-sen University

Eligibility Criteria

Inclusion Criteria

•Locally advanced non-small cell lung cancer, limited-stage small cell lung cancer, and esophageal cancer.
•Planned to undergo definitive chemoradiotherapy ± immunotherapy;
•Males or females aged 18 to 75;
•Able to communicate with medical staff.